Purdue diabetic licence cancelled
Japanese company Kissei and Purdue Pharma of the US are to terminate the licence agreement for Kissei's antidiabetic drug mitiglinide. The ongoing US clinical studies will be transferred to Kissei's US subsidiary. The drug is currently in early Phase II trials.